Drawing for Serial No. 79309610

USPTO serial 79309610

Serial No. 79309610

Reviewed by CopyMark Law Group

Reg. 6703567Status 700Registered
Filing date
Status date
Registration date
Apr 19, 2022
Examiner
HACK, ANDREA R
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with Serial No. 79309610?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Roger D. Emerson, Esq.

Roger D. Emerson, Esq. EMERSON THOMSON BENNETT1914 Akron-Peninsula RoadAkron, OH 44313UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Biochemical catalysts; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical reagents, other than for medical or veterinary purposes; chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; chemical substances for analyses in laboratories, other than for medical or veterinary purposes; diagnostic preparations other than for medical or veterinary purposes; biological preparations for use in cell cultures other than for medical or veterinary use; active chemical ingredients for use in the manufacture of pharmaceuticals for treating breast cancer or diabetes, which refers to, namely, the raw drug materials used in the production of various preparations, are the effective ingredients in the preparations, and the powders, crystals and extracts prepared by chemical synthesis, plant extraction or biotechnology, are used for medicinal purposes, but the substances cannot be taken by patientsACTIVE—
005Diagnostic preparations for veterinary purposes; amino acids for veterinary purposes; chemical preparations for treating mildew; chemical reagents for medical or veterinary purposes; chemical preparations for pharmaceutical or medical purposes, namely, for breast cancer or diabetes and liposome pharmaceutical reagents for mRNA vaccines; biological preparations for the treatment of breast cancer or diabetes; guaiacol for pharmaceutical purposes; chemicopharmaceutical preparations for the prevention and treatment of cancer or diabetesACTIVE—
042Conducting clinical trials for others in the field of breast cancer; chemistry services customized according to customer contract; chemistry servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 26, 2022FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 1, 2022FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 1, 2022FIMPFINAL DISPOSITION PROCESSED—
Jul 19, 2022FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Apr 19, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 1, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 1, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 30, 2022GPNXNOTIFICATION PROCESSED BY IB—
Jan 12, 2022OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jan 12, 2022OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jan 12, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 29, 2021PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Dec 29, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 29, 2021ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Dec 22, 2021ALIEASSIGNED TO LIE—
Dec 22, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 22, 2021ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Dec 22, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 21, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 21, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 21, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 22, 2021DOCKASSIGNED TO EXAMINER—
Jul 11, 2021RFNTREFUSAL PROCESSED BY IB—
Jun 22, 2021RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 22, 2021RFRRREFUSAL PROCESSED BY MPU—
Jun 12, 2021RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 11, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 12, 2021DOCKASSIGNED TO EXAMINER—
May 4, 2021MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 30, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 29, 2021REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance